RWA Wealth Partners LLC Acquires New Stake in United Therapeutics Co. (NASDAQ:UTHR)

RWA Wealth Partners LLC bought a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR) in the fourth quarter, Holdings Channel reports. The firm bought 2,332 shares of the biotechnology company’s stock, valued at approximately $513,000.

Several other institutional investors also recently bought and sold shares of the company. Duality Advisers LP boosted its stake in shares of United Therapeutics by 56.1% in the fourth quarter. Duality Advisers LP now owns 15,642 shares of the biotechnology company’s stock valued at $3,440,000 after purchasing an additional 5,622 shares during the period. Handelsbanken Fonder AB lifted its holdings in United Therapeutics by 8.9% during the 4th quarter. Handelsbanken Fonder AB now owns 8,600 shares of the biotechnology company’s stock worth $1,891,000 after buying an additional 700 shares in the last quarter. CWM LLC boosted its position in United Therapeutics by 45.7% in the 4th quarter. CWM LLC now owns 670 shares of the biotechnology company’s stock valued at $147,000 after buying an additional 210 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in shares of United Therapeutics by 1.6% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,892 shares of the biotechnology company’s stock worth $856,000 after acquiring an additional 61 shares in the last quarter. Finally, abrdn plc acquired a new position in shares of United Therapeutics in the fourth quarter worth $6,218,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

UTHR has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. The Goldman Sachs Group raised United Therapeutics from a “sell” rating to a “neutral” rating and boosted their price objective for the stock from $213.00 to $215.00 in a research report on Monday, February 12th. Leerink Partnrs reaffirmed an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. Finally, SVB Leerink assumed coverage on shares of United Therapeutics in a research note on Monday, February 5th. They issued an “outperform” rating and a $330.00 price target for the company. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $294.25.

United Therapeutics Stock Down 0.4 %

Shares of NASDAQ:UTHR opened at $235.95 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28. The stock has a market cap of $11.10 billion, a P/E ratio of 11.89 and a beta of 0.52. United Therapeutics Co. has a 1-year low of $204.44 and a 1-year high of $261.54. The firm has a fifty day moving average price of $233.36 and a 200 day moving average price of $228.79.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping the consensus estimate of $4.28 by $0.08. The business had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The business’s quarterly revenue was up 25.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.67 earnings per share. Sell-side analysts predict that United Therapeutics Co. will post 23.45 EPS for the current year.

Insiders Place Their Bets

In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $215.31, for a total transaction of $1,291,860.00. Following the transaction, the executive vice president now directly owns 36,599 shares in the company, valued at $7,880,130.69. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $215.31, for a total transaction of $1,291,860.00. Following the completion of the sale, the executive vice president now directly owns 36,599 shares in the company, valued at approximately $7,880,130.69. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Christopher Patusky sold 1,680 shares of the company’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $224.00, for a total value of $376,320.00. Following the completion of the sale, the director now owns 4 shares in the company, valued at approximately $896. The disclosure for this sale can be found here. Over the last quarter, insiders sold 136,990 shares of company stock worth $32,239,641. 12.50% of the stock is owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.